2025 North America Anti-Migraine Drugs Market Revenue Opportunities Report
Description
The 2025 North America Anti-Migraine Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American anti-migraine drugs market are AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Eli Lilly and Company. AbbVie is a leader with its Botox product used for migraine prevention and continues advancing through innovative therapies. Amgen markets Aimovig (erenumab), a CGRP monoclonal antibody targeting migraine prophylaxis, showing strong growth due to its efficacy and patient adoption. Teva is prominent with its CGRP inhibitor Ajovy (fremanezumab), recently pursuing expanded approval for pediatric use. Eli Lilly is known for Emgality (galcanezumab), another CGRP antagonist widely adopted for preventive treatment in adults.
These companies dominate due to their robust R&D pipelines, frequent regulatory approvals, and novel product launches tailored for the North American market, which is the largest region globally for migraine drug sales. Partnership strategies and focus on both acute and preventive migraine therapies, including CGRP inhibitors and combination treatments, drive their market share. The North American migraine drugs market, valued over $3 billion in 2024, is expected to grow rapidly, fueled by high migraine prevalence and advanced healthcare infrastructure supporting these companies’ expansion efforts.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American anti-migraine drugs market are AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Eli Lilly and Company. AbbVie is a leader with its Botox product used for migraine prevention and continues advancing through innovative therapies. Amgen markets Aimovig (erenumab), a CGRP monoclonal antibody targeting migraine prophylaxis, showing strong growth due to its efficacy and patient adoption. Teva is prominent with its CGRP inhibitor Ajovy (fremanezumab), recently pursuing expanded approval for pediatric use. Eli Lilly is known for Emgality (galcanezumab), another CGRP antagonist widely adopted for preventive treatment in adults.
These companies dominate due to their robust R&D pipelines, frequent regulatory approvals, and novel product launches tailored for the North American market, which is the largest region globally for migraine drug sales. Partnership strategies and focus on both acute and preventive migraine therapies, including CGRP inhibitors and combination treatments, drive their market share. The North American migraine drugs market, valued over $3 billion in 2024, is expected to grow rapidly, fueled by high migraine prevalence and advanced healthcare infrastructure supporting these companies’ expansion efforts.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
